Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
C4 Therapeutics, Inc. | Chief Financial Officer | Common Stock | 84.4K | $510K | $6.04 | Nov 7, 2024 | Direct |
C4 Therapeutics, Inc. | Chief Financial Officer | Performance Restricted Stock Units | 10.5K | $63.4K | $6.04 | Nov 7, 2024 | Direct |
C4 Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 45K | Mar 7, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
CCCC | C4 Therapeutics, Inc. | Nov 7, 2024 | 3 | -$6.66K | 4 | Nov 12, 2024 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Sep 18, 2024 | 1 | -$11.7K | 4 | Sep 20, 2024 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Sep 16, 2024 | 3 | -$4.2K | 4 | Sep 17, 2024 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Mar 7, 2024 | 2 | $0 | 4 | Mar 8, 2024 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Feb 13, 2024 | 3 | -$8.5K | 4 | Feb 15, 2024 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Sep 18, 2023 | 2 | $0 | 4 | Sep 19, 2023 | Chief Financial Officer |
CCCC | C4 Therapeutics, Inc. | Sep 18, 2023 | 0 | $0 | 3 | Sep 19, 2023 | Chief Financial Officer |